Dr. Dea Belazi PharmD, MPH, PAHM
Pharmacy Consultant, Dea Belazi, PharmD, MPH, PAHM
Member of the Healthcare Council
Council Member Biography
Dea Belazi, PharmD, MPH, PAHM, is currently a Consultant working with health plans and pharmaceutical companies. Dr. Belazi is also a Consulting Practice Leader for Wolters Kluwer Health- Managed Care Group. Previously, he was the Senior Director of Pharmacy Services for Independence Blue Cross, a large commercial and Medicare health plan in Pennsylvania. Prior to that, Dr. Belazi was the Associate Vice President of Clinical Programs for Keystone and AmeriHealth Mercy Health Plans. His experience includes pharmaco economics, outcomes research, epidemiology, and pharmacy benefit management. His responsibilities include national formulary management, disease management programs, effectiveness studies of pharmaceuticals, and pharmacy benefit program implementations. Dr. Belazi also holds faculty positions at the University of Rhode Island and Thomas Jefferson University. (This is me - Update Profile)
Employment History
- 2006 - Unspecified
- Pharmacy Consultant, Dea Belazi, PharmD, MPH, PAHM
- 2005 - 2006
- Senior Director of Pharmacy Services, INDEPENDENCE BLUE CROSS
- 2001 - 2005
- Associate Vice President, Clinical Programs, KEYSTONE MERCY HEALTH PLAN
GLG NewsSM Analyses by Dea Belazi(?)
Opinions and analyses expressed in GLG News are solely those of the author. See the Terms of Use for details.
-
January 28, 2008
FDA Receives New Data on Risks of Anemia Drugs | www.fda.gov
Increased FDA warnings on ESAs, suchas Epogen, Procrit and Aranesp will provide payers the ability to further restrict these agents. Restrictions will come in the form of prior authorizations and other utilization management techniques.
-
Perhaps the Most Important Reason for Exubera Failure is that No One Wanted to Pay for it
October 29, 2007
Pfizer Abandons Exubera, Posts 77% Earnings Decline | online.wsj.com
Pfizers failure on Exubera were not of safety issues, or complicated device, or even consumer marketing problems. Their biggest issue that brought failure was the lack of payer coverage. Almost no payer in the US added Exubera to their formulary or saw any value over injectable insulin at the price being commanded by Pfizer.
-
WalMart Expansion of $4 generics
October 3, 2007
Wal-Mart Expands Offerings Of $4 Generic Drugs | online.wsj.com
WalMarts strategy on expanding $4 generics is not at a loss. They are taking a number of generics (in the hunderds) that are nominaly priced and selling them to consumers and still making a profit.
-
Indian Pharmaceutical Manufacturers
October 3, 2007
Drug discovery hits India | www.icis.com
Indian manufacturers such as Aurabindo, Reddy, Ranbaxy and others are getting on the shelves at the local pharmacies.
Leading institutions connect with Dea Belazi through GLG
GLG Study Groups with Dea Belazi(?)
| Study Group Name | No. Members |
|---|---|
| Experts in the Leisure & Lodging Council | 4887 |
| Experts in the Automotive Council | 3422 |
| Pharmacists (US) | 2077 |
| Generic Drug Economic Experts | 766 |
| Economic Experts on Managed Care | 714 |
GLG Live Meetings with Dea Belazi(?)
Recent Seminars
-
July 31, 2007 | Boston
GLGi: Managed Care Formulary -
July 30, 2007 | New York
GLGi: Managed Care Formulary